Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 18/20 | 0.51 |
| ▸ | OXTR | P30559 | 7/20 | 0.51 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.43 |
| ▸ | AVPR1B | P47901 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6202295 | 0.80 | AVPR1A (0.46) | AVPR2OXTRAVPR1AAVPR1B | |
| SCHEMBL1660513 | 0.80 | AVPR2 (0.67) | AVPR2OXTRAVPR1AAVPR1B | |
| SCHEMBL5429019 | 0.80 | AVPR2 (0.67) | AVPR2OXTRAVPR1AAVPR1B | |
| SCHEMBL6202773 | 0.77 | AVPR1A (0.55) | AVPR2OXTRAVPR1AAVPR1B | |
| SCHEMBL4835299 | 0.76 | AVPR1A (0.54) | AVPR2OXTRAVPR1AAVPR1B | |
| Trifluoroacetic Acid SCHEMBL6202890 | 0.76 | AVPR2 (0.62) | AVPR2OXTRAVPR1AAVPR1B | |
| SCHEMBL6202298 | 0.74 | AVPR2 (0.46) | AVPR2OXTRAVPR1AAVPR1B | |
| SCHEMBL38963 | 0.74 | AVPR2 (0.47) | AVPR2OXTRAVPR1AAVPR1B | |
| SCHEMBL4835899 | 0.74 | AVPR2 (0.60) | AVPR2OXTR | |
| SCHEMBL6202894 | 0.72 | AVPR2 (0.53) | AVPR2OXTRAVPR1AAVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050032777-A1 | Diazacycloalkanes as oxytocin agonists | FEERING B.V. (NL) | 2005-02-10 | — | — | US | disclosed |
| EP-1421087-A1 | DIAZACYCLOALKANES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003016316-A1 | DIAZACYCLOALKANES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2003-02-27 | — | — | WO | disclosed |
| WO-2003016316-A1 | DIAZACYCLOALKANES AS OXYTOCIN AGONISTS | FERRING B.V. (NL) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032777-A1 | Diazacycloalkanes as oxytocin agonists | OXTR, GNRHR, KISS1R | AVPR2 15/4885OXTR 1/4885AVPR1A 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.